Carroll Financial Associates Inc. boosted its stake in Bristol-Myers Squibb Co (NYSE:BMY) by 1.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 17,024 shares of the biopharmaceutical company’s stock after purchasing an additional 248 shares during the period. Carroll Financial Associates Inc.’s holdings in Bristol-Myers Squibb were worth $824,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Arlington Partners LLC grew its holdings in Bristol-Myers Squibb by 40.0% during the 4th quarter. Arlington Partners LLC now owns 1,400 shares of the biopharmaceutical company’s stock worth $73,000 after acquiring an additional 400 shares during the period. Curbstone Financial Management Corp grew its holdings in Bristol-Myers Squibb by 4.6% during the 4th quarter. Curbstone Financial Management Corp now owns 12,542 shares of the biopharmaceutical company’s stock worth $652,000 after acquiring an additional 550 shares during the period. Wealth Architects LLC grew its holdings in Bristol-Myers Squibb by 14.0% during the 3rd quarter. Wealth Architects LLC now owns 6,923 shares of the biopharmaceutical company’s stock worth $430,000 after acquiring an additional 848 shares during the period. Beech Hill Advisors Inc. grew its holdings in Bristol-Myers Squibb by 0.8% during the 3rd quarter. Beech Hill Advisors Inc. now owns 105,500 shares of the biopharmaceutical company’s stock worth $6,549,000 after acquiring an additional 850 shares during the period. Finally, Signature Financial Management Inc. grew its holdings in Bristol-Myers Squibb by 1.9% during the 2nd quarter. Signature Financial Management Inc. now owns 46,006 shares of the biopharmaceutical company’s stock worth $2,546,000 after acquiring an additional 870 shares during the period. Institutional investors and hedge funds own 72.68% of the company’s stock.
A number of analysts have weighed in on the company. ValuEngine upgraded Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a report on Friday, December 7th. Morgan Stanley set a $54.00 price target on Bristol-Myers Squibb and gave the stock a “hold” rating in a report on Thursday, December 20th. Zacks Investment Research downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Thursday, January 3rd. JPMorgan Chase & Co. raised their target price on Bristol-Myers Squibb from $70.00 to $74.00 and gave the company an “overweight” rating in a research note on Monday, October 8th. Finally, Edward Jones downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Friday, January 4th. Three research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and seven have assigned a buy rating to the company. Bristol-Myers Squibb presently has a consensus rating of “Hold” and an average target price of $61.56.
Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, October 25th. The biopharmaceutical company reported $1.09 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.91 by $0.18. The company had revenue of $5.69 billion during the quarter, compared to the consensus estimate of $5.72 billion. Bristol-Myers Squibb had a return on equity of 47.89% and a net margin of 6.50%. On average, sell-side analysts forecast that Bristol-Myers Squibb Co will post 3.88 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, February 1st. Investors of record on Friday, January 4th will be given a $0.41 dividend. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.40. The ex-dividend date is Thursday, January 3rd. This represents a $1.64 annualized dividend and a yield of 3.42%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 54.49%.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.
Recommended Story: Are 12b-1 Fees Affecting Your Mutual Fund Performance?
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.